{"transactions":[{"id":3005531,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Options to purchase Common Stock","published_at":"2020-10-16T22:58:40.000Z","date":"2020-10-14","kind":"gift","acquired":false,"shares":3000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These options are gifts from Ms. Powers for no consideration."}],"balance_after":29558724,"derivative":{"exercise_price":0.25,"exercise_date":"2020-12-01","expiration_date":"2030-12-01","underlying":"Common Stock, par value $0.001 per share","underlying_shares":3000000},"source":{"system":"sec-edgar","filing":"0001104659-20-115717","document":"tm2022243d17_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465920115717/tm2022243d17_4.xml","form_type":"4"}},{"id":3092690,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Options to purchase Common Stock, par value $0.001","published_at":"2020-07-03T01:55:51.000Z","date":"2020-07-02","kind":"grant","acquired":true,"shares":8665524,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These options were approved in January 2020.  The exercise price was determined based upon the pricing in year-end financings with unrelated investors.  However, these options have not been executed and implemented (granted) until now."}],"balance_after":8665524,"derivative":{"exercise_price":0.21,"exercise_date":"2020-07-02","expiration_date":"2030-07-02","underlying":"Common Stock, par value $0.001","underlying_shares":8665524},"source":{"system":"sec-edgar","filing":"0001104659-20-080814","document":"tm2022243d14_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465920080814/tm2022243d14_4.xml","form_type":"4"}},{"id":3092689,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Options to purchase Common Stock, par value $0.001","published_at":"2020-07-03T01:55:51.000Z","date":"2020-07-02","kind":"grant","acquired":true,"shares":2104905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These options were already approved and publicly reported in 2018. The exercise price was determined with reference to the pricing for unrelated investors at that time. However, the documents to implement and issue (grant) them have not been executed until now."}],"balance_after":2104905,"derivative":{"exercise_price":0.25,"exercise_date":"2020-07-02","expiration_date":"2030-07-02","underlying":"Common Stock, par value $0.001","underlying_shares":2104905},"source":{"system":"sec-edgar","filing":"0001104659-20-080814","document":"tm2022243d14_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465920080814/tm2022243d14_4.xml","form_type":"4"}},{"id":3092688,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Options to purchase Common Stock, par value $0.001","published_at":"2020-07-03T01:55:49.000Z","date":"2020-07-02","kind":"grant","acquired":true,"shares":32558724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These options were awarded in part for service during the last 2 years. However, the documents to implement and issue (grant) them have not been executed until now. The $0.25 exercise price was determined with reference to the pricing for unrelated investors at the time of approval, which was the trailing 10-day average closing market price of the Company's stock, which was about $0.22. These options are subject to certain vesting requirements. They are also suspended and will not become exercisable until December 1, 2020."}],"balance_after":32558724,"derivative":{"exercise_price":0.25,"exercise_date":"2020-12-01","expiration_date":"2030-12-01","underlying":"Common Stock, par value $0.001","underlying_shares":32558724},"source":{"system":"sec-edgar","filing":"0001104659-20-080813","document":"tm2022243d13_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465920080813/tm2022243d13_4.xml","form_type":"4"}},{"id":3092677,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Warrants to purchase Common Stock","published_at":"2020-07-03T01:53:23.000Z","date":"2020-07-02","kind":"grant","acquired":true,"shares":15249474,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These warrants were in partial consideration of Ms. Powers' loans of $5.4 million to the Company and forbearance on the repayment of those loans. These warrants were approved and publicly reported in 2018. However, the documents to implement and issue (grant) these warrants were not executed until now. The exercise price was determined with reference to the price per share paid by unrelated investors."}],"balance_after":15249474,"derivative":{"exercise_price":0.21,"exercise_date":"2020-11-01","expiration_date":"2025-11-01","underlying":"Common Stock, par value $0.001 per share","underlying_shares":15249474},"source":{"system":"sec-edgar","filing":"0001104659-20-080806","document":"tm2023608d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465920080806/tm2023608d1_4.xml","form_type":"4"}},{"id":3165588,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Warrants","published_at":"2020-05-02T01:12:20.000Z","date":"2020-04-30","kind":"other","acquired":true,"shares":29411760,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"J is the transaction code for \"other acquisitions\". It covers the deemed issuance of replacement warrants."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This portion of existing warrants held by Ms. Powers was extended in consideration for suspension of these warrants making them unexercisable until Nov. 1, 2020, and for suspension of other warrants held by Ms. Powers making those unexercisable until Nov. 1, 2020 as well. These extended warrants will have an exercise period of 2-1/2 years after the suspension period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This portion of existing warrants held by Ms. Powers was extended in consideration for suspension of these warrants making them unexercisable until Nov. 1, 2020, and for suspension of other warrants held by Ms. Powers making those unexercisable until Nov. 1, 2020 as well. These extended warrants will have an exercise period of 2-1/2 years after the suspension period."}],"balance_after":29411760,"derivative":{"exercise_price":0.22,"exercise_date":"2020-11-01","expiration_date":"2023-05-01","underlying":"Common Stock, par value $0.001","underlying_shares":29411760},"source":{"system":"sec-edgar","filing":"0001104659-20-055770","document":"tm2018427d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465920055770/tm2018427d1_4.xml","form_type":"4"}},{"id":3165587,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Warrants","published_at":"2020-05-02T01:12:20.000Z","date":"2020-04-30","kind":"other","acquired":false,"shares":29411760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Extension of an existing warrant is deemed to be a cancellation and re-issuance. H is the transaction code which covers cancellation of securities."}],"balance_after":0,"derivative":{"exercise_price":0.22,"exercise_date":"2018-05-02","expiration_date":"2020-05-02","underlying":"Common Stock, par value $0.001","underlying_shares":29411760},"source":{"system":"sec-edgar","filing":"0001104659-20-055770","document":"tm2018427d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465920055770/tm2018427d1_4.xml","form_type":"4"}},{"id":3298648,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-29T20:39:06.000Z","date":"2020-01-27","kind":"sale","acquired":false,"shares":220000,"price":4.6,"value":1012000.0,"ownership":{"direct":true},"balance_after":210000,"source":{"system":"sec-edgar","filing":"0001104659-20-008253","document":"tv537330_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1289624/000110465920008253/tv537330_4.xml","form_type":"4"}},{"id":3684035,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Class D-2 Warrants","published_at":"2019-01-30T02:57:33.000Z","date":"2018-12-27","kind":"sale","acquired":false,"shares":1779320,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.3,"exercise_date":"2018-05-04","expiration_date":"2023-05-04","underlying":"Common Stock, par value $0.001","underlying_shares":1779320},"source":{"system":"sec-edgar","filing":"0001144204-19-003609","document":"tv511975_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000114420419003609/tv511975_4.xml","form_type":"4"}},{"id":3684034,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Class D-2 Warrants","published_at":"2019-01-30T02:57:33.000Z","date":"2018-12-28","kind":"sale","acquired":false,"shares":402073,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Sale by Toucan Capital Fund III, LP."},"balance_after":0,"derivative":{"exercise_price":0.3,"exercise_date":"2018-05-04","expiration_date":"2023-05-04","underlying":"Common Stock, par value $0.001","underlying_shares":402073},"source":{"system":"sec-edgar","filing":"0001144204-19-003609","document":"tv511975_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000114420419003609/tv511975_4.xml","form_type":"4"}},{"id":3684033,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Common Stock, par value $0.001","published_at":"2019-01-30T02:57:33.000Z","date":"2018-12-27","kind":"sale","acquired":false,"shares":3558639,"price":0.17,"value":604968.63,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting party sold shares of restricted common stock."}],"balance_after":29411760,"source":{"system":"sec-edgar","filing":"0001144204-19-003609","document":"tv511975_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000114420419003609/tv511975_4.xml","form_type":"4"}},{"id":3684032,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Common Stock, par value $0.001","published_at":"2019-01-30T02:57:33.000Z","date":"2018-12-28","kind":"sale","acquired":false,"shares":804146,"price":0.17,"value":136704.82,"ownership":{"direct":false,"nature":"Sale by Toucan Capital Fund III, LP."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Toucan Capital Fund III, LP sold the 804,146 restricted shares of common stock that it owned, in preparation for the required dissolution due to the Toucan Fund reaching the end of its contractual term. The reporting person has management control as well as a partnership interest in the Toucan Fund."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001144204-19-003609","document":"tv511975_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000114420419003609/tv511975_4.xml","form_type":"4"}},{"id":3914361,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options to purchase Common Stock, par value $0.001","published_at":"2018-05-31T01:59:11.000Z","date":"2018-05-28","kind":"grant","acquired":true,"shares":39200000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"29,400,000 of these 39,200,000 Options were previously reported on Form 8-K on January 16, 2018, following Board approval.  Half of the Options are vested at the time of issuance and half will vest monthly over the course of 24 months from the date of Board approval, subject to acceleration in certain circumstances."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The exercise price of the Options is $0.23."}],"balance_after":39200000,"derivative":{"exercise_price":0.23,"exercise_date":"2018-05-28","expiration_date":"2028-05-28","underlying":"Common Stock, par value $0.001","underlying_shares":39200000},"source":{"system":"sec-edgar","filing":"0001144204-18-031801","document":"tv495286_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000114420418031801/tv495286_4.xml","form_type":"4"}},{"id":3985301,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class D-2 Warrants","published_at":"2018-03-23T00:38:53.000Z","date":"2018-03-19","kind":"grant","acquired":true,"shares":869565,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"As disclosed in the original filing and in footnote 1, certain Class D-2 Warrants were issued in connection with the notes issuance.  This amendment is filed to further indicate the amount of such warrants."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."}],"balance_after":869565,"derivative":{"exercise_price":0.3,"exercise_date":"2018-03-19","underlying":"Common Stock","underlying_shares":869565},"source":{"system":"sec-edgar","filing":"0001144204-18-016504","document":"tv489355_4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000114420418016504/tv489355_4a.xml","form_type":"4/A","original_submission_date":"2018-03-21"}},{"id":3985300,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Convertible Note","published_at":"2018-03-23T00:38:53.000Z","date":"2018-03-19","kind":"grant","acquired":true,"reported_value":400000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F1","text":"The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."}],"derivative":{"exercise_date":"2018-03-19","underlying":"Class D-2 Warrants","underlying_shares":869565},"source":{"system":"sec-edgar","filing":"0001144204-18-016504","document":"tv489355_4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000114420418016504/tv489355_4a.xml","form_type":"4/A","original_submission_date":"2018-03-21"}},{"id":3985299,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Convertible Note","published_at":"2018-03-23T00:38:53.000Z","date":"2018-03-19","kind":"grant","acquired":true,"reported_value":400000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F1","text":"The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."}],"derivative":{"exercise_date":"2018-03-19","underlying":"Series B Preferred Stock","underlying_shares":173913},"source":{"system":"sec-edgar","filing":"0001144204-18-016504","document":"tv489355_4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000114420418016504/tv489355_4a.xml","form_type":"4/A","original_submission_date":"2018-03-21"}},{"id":3986554,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Convertible Note","published_at":"2018-03-22T00:12:10.000Z","date":"2018-03-19","kind":"grant","acquired":true,"reported_value":400000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F1","text":"The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."}],"derivative":{"exercise_date":"2018-03-19","underlying":"Class D-2 Warrants","underlying_shares":869565},"source":{"system":"sec-edgar","filing":"0001144204-18-016240","document":"tv489185_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000114420418016240/tv489185_form4.xml","form_type":"4"}},{"id":3986553,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Convertible Note","published_at":"2018-03-22T00:12:10.000Z","date":"2018-03-19","kind":"grant","acquired":true,"reported_value":400000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F1","text":"The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."}],"derivative":{"exercise_date":"2018-03-19","underlying":"Series B Preferred Stock","underlying_shares":173913},"source":{"system":"sec-edgar","filing":"0001144204-18-016240","document":"tv489185_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000114420418016240/tv489185_form4.xml","form_type":"4"}},{"id":3996642,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class D-1 Warrants","published_at":"2018-03-15T01:04:51.000Z","date":"2018-03-12","kind":"other","acquired":true,"shares":29411760,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported transactions are exempt from Section 16(b) of the Exchange Act because the securities were received by the reporting person as payment of $5 million of debt previously contracted and owed by a third party to the reporting person (which was part of a larger debt previously contracted by the third party to the reporting person which was unpaid) as the third party was unable to make any repayment in cash."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"A $5 million portion of a larger pre-existing debt owed by a third party to the reporting person was paid by assignment of this Series A Preferred Stock and Class D-1 Warrants to the reporting person as the third party was unable to make any repayment in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Convertible and exercisable when the Company has sufficient shares of common stock authorized and available. The Class D-1 Warrants are not currently exercisable and will expire two years after they become exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Convertible and exercisable when the Company has sufficient shares of common stock authorized and available. The Class D-1 Warrants are not currently exercisable and will expire two years after they become exercisable."}],"balance_after":29411760,"derivative":{"exercise_price":0.22,"underlying":"Common Stock","underlying_shares":29411760},"source":{"system":"sec-edgar","filing":"0001144204-18-014763","document":"tv488530_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000114420418014763/tv488530_4.xml","form_type":"4"}},{"id":3996641,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Series A Preferred Stock","published_at":"2018-03-15T01:04:51.000Z","date":"2018-03-12","kind":"other","acquired":true,"shares":2941176,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported transactions are exempt from Section 16(b) of the Exchange Act because the securities were received by the reporting person as payment of $5 million of debt previously contracted and owed by a third party to the reporting person (which was part of a larger debt previously contracted by the third party to the reporting person which was unpaid) as the third party was unable to make any repayment in cash."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"A $5 million portion of a larger pre-existing debt owed by a third party to the reporting person was paid by assignment of this Series A Preferred Stock and Class D-1 Warrants to the reporting person as the third party was unable to make any repayment in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Convertible and exercisable when the Company has sufficient shares of common stock authorized and available. The Class D-1 Warrants are not currently exercisable and will expire two years after they become exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Convertible and exercisable when the Company has sufficient shares of common stock authorized and available. The Class D-1 Warrants are not currently exercisable and will expire two years after they become exercisable."}],"balance_after":2941176,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":29411760},"source":{"system":"sec-edgar","filing":"0001144204-18-014763","document":"tv488530_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000114420418014763/tv488530_4.xml","form_type":"4"}},{"id":3996640,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class D-2 Warrants","published_at":"2018-03-15T01:04:51.000Z","date":"2018-03-14","kind":"grant","acquired":true,"shares":8695652,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."}],"balance_after":8695652,"derivative":{"exercise_price":0.3,"exercise_date":"2018-03-14","underlying":"Common Stock","underlying_shares":8695652},"source":{"system":"sec-edgar","filing":"0001144204-18-014763","document":"tv488530_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000114420418014763/tv488530_4.xml","form_type":"4"}},{"id":3996639,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Convertible Note","published_at":"2018-03-15T01:04:51.000Z","date":"2018-03-14","kind":"grant","acquired":true,"reported_value":4000000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"reported_value","element":"transactionTotalValue","label":"F1","text":"The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F1","text":"The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."}],"derivative":{"exercise_date":"2018-03-14","underlying":"Class D-2 Warrants","underlying_shares":8695652},"source":{"system":"sec-edgar","filing":"0001144204-18-014763","document":"tv488530_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000114420418014763/tv488530_4.xml","form_type":"4"}},{"id":3996638,"issuer":{"id":5982,"kind":"organization","name":"NORTHWEST BIOTHERAPEUTICS INC"},"owners":[{"id":145922,"kind":"person","name":"Powers Linda F","position":1,"cik":"0001289624","reported_name":"Powers Linda F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Convertible Note","published_at":"2018-03-15T01:04:51.000Z","date":"2018-03-14","kind":"grant","acquired":true,"reported_value":4000000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"reported_value","element":"transactionTotalValue","label":"F1","text":"The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F1","text":"The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30."}],"derivative":{"exercise_date":"2018-03-14","underlying":"Series B Preferred Stock","underlying_shares":1739130},"source":{"system":"sec-edgar","filing":"0001144204-18-014763","document":"tv488530_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1072379/000114420418014763/tv488530_4.xml","form_type":"4"}}]}